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Abstract Mutations in the neuro¢bromatosis type 1 (NF1) tu-
mor suppressor gene predispose individuals to a variety of be-
nign and malignant tumors. Many tumor suppressors ‘shuttle’
between the nucleus and the cytoplasm, thus regulating their
function. By expressing di¡erent NF1 constructs in COS-7 cells
(encompassing exons 28^49 and fused to the green £uorescent
protein), we identi¢ed a functional nuclear localization signal
(NLS) in exon 43. Mutation of the NLS completely abolishes
the nuclear entry of the NF1-derivative fusion protein. A highly
expressed splice variant that lacks this NLS controls the local-
ization and hence the function of neuro¢bromin. The localiza-
tion of neuro¢bromin in the nucleus may provide novel clues to
unknown functions for NF1.
5 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Neuro¢bromatosis type 1 (NF1) is a common autosomal
dominant disorder a¡ecting V1 in 3000 individuals. The
NF1 gene spans V350 kb of genomic DNA and produces a
11^13 kb transcript containing 60 exons [1^3]. Mutation of
the NF1 gene leads to diverse clinical outcomes. The most
common manifestations are cafe¤-au-lait macules, neuro¢bro-
mas, Lisch nodules, axillary freckling and learning disabilities
[4]. The NF1 gene is classi¢ed as a tumor suppressor gene
since decrease or absence of NF1 protein is seen in malignant
tumor cell lines from patients, loss of heterozygosity is seen in
malignant tumors of NF1 patients and somatic mutations
have been found in sporadic cancers of non-NF1 patients
[5^10]. Neuro¢bromin, the NF1 protein product, is a large
protein of 2818 amino acids and is ubiquitously expressed,
although the protein levels di¡er in di¡erent tissues and in
developmental or functional states [11^13]. There is no abso-
lute correlation of protein expression with the disease as neu-
ro¢bromin is expressed in both a¡ected and phenotypically
una¡ected tissues in NF1 patients. The pleiotropic NF1 dis-
ease manifestations cannot be explained by the current knowl-
edge of the function of NF1 and much remains to be eluci-
dated about the regulation of this huge gene and the function
of its protein.
Analysis of the NF1 protein sequence has revealed that a
central domain is homologous to a family of proteins known
as Ras-GTPase activating proteins (Ras-GAPs), which func-
tion as negative regulators for Ras proteins [14]. The Gap-
related domain (GRD) spans 250^400 amino acids, represent-
ing only about 10% of the protein sequence [15^17]. While the
vast majority of NF1 research has been focused on the GRD,
evidence for other important functional domains within neu-
ro¢bromin is supported by the existence of pathogenic mis-
sense mutations outside the GRD [18,19], alternatively spliced
NF1 transcripts [20] and the large size of the protein.
Tumor suppressor proteins are regulated by a number of
di¡erent strategies to avoid abnormal cellular growth. Over
the past few years it has been shown that many tumor sup-
pressor genes ‘shuttle’ between the nucleus and the cytoplasm
[21]. This type of dynamic intracellular movement regulates
not only protein localization, but also protein function. Neu-
ro¢bromin appears to be predominantly cytoplasmic, with
di¡erent cell types displaying a variable subcellular localiza-
tion. Some studies have also observed neuro¢bromin in the
nucleus [12,22^24], but the function in the nucleus and the
regulation of nuclear importation remain unknown. More-
over, the scarce reports about nuclear neuro¢bromin, the
small number of cells displaying nuclear localization, possible
non-speci¢c staining of damaged cells, as well as lack of spec-
i¢city of the antibodies have cast uncertainty on the nuclear
localization of neuro¢bromin [12,23].
Previously, we have demonstrated the existence of a highly
expressed splice variant at the C-terminal end of NF1. This
variant consists of an in-frame deletion of exon 43 (NF1-
vE43) and lacks an in silico predicted bipartite nuclear local-
ization signal (bipartite NLS, i.e. two basic amino acid
stretches, separated by a 10^12 amino acid variable spacer)
[22,25]. This variant is highly expressed in fetal and adult
liver, skeletal muscle, kidney, placenta and lung [25]. In the
current study we report the intracellular localization of this
splice variant determined by expressing di¡erent C-terminal
constructs either containing or lacking exon 43. We show
that inclusion of exon 43 can target the NF1 fusion protein
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to the nucleus, whereas exclusion of exon 43 completely abol-
ishes this nuclear localization. Hence alternative splicing of
exon 43 can control the localization and the function of neu-
ro¢bromin by regulating transfer to the nucleus. We charac-
terize this NLS by site-directed mutagenesis.
2. Materials and methods
2.1. Plasmid construction
Primers were designed that amplify exons 28^49 (amino acids 1591^
2805) of the NF1 coding region. Addition of XmaI and SacII restric-
tion sites to the primers allowed ligation to the XmaI/SacII-digested
pEGFP-C1 vector (Clontech), resulting in an in-frame fusion to the
C-terminus of the green £uorescent protein (GFP). Site-directed muta-
genesis was performed using the QuickChange XL site-directed muta-
genesis kit (Stratagene), using primers that speci¢cally introduced
the desired mutations (K2534A, R2535A, K2547A, R2549A and
R2550A). All constructs were checked for sequence integrity on an
ABI 3100 capillary system (Applied Biosystems) before and after bulk
preparation of the desired plasmids.
2.2. Cell culture and transfections
COS-7 cells and PLC/PRF/5 cells (human liver hepatoma cells)
were grown in Dulbecco’s modi¢ed Eagle’s medium (Invitrogen) sup-
plemented with 10% fetal calf serum at 37‡C in a 5% CO2 atmosphere.
For transient transfection experiments, cells were grown on glass cov-
erslips in a 24 well plate to approximately 90% con£uence and 0.8 Wg
of each GFP expression construct was transfected into the cells using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s in-
structions. The transfected cells were cultured for 24 h in serum-con-
taining medium before subcellular localization analysis.
2.3. Subcellular localization analysis
Cells were ¢xed in 3% paraformaldehyde for 15 min at room tem-
perature, washed with phosphate-bu¡ered saline and incubated for
5 min with 300 nM DAPI (Sigma). After washing, the coverslips
were mounted in VectaShield (Vector Laboratories). The subcellular
localization of the GFP fusion proteins was visualized on a Blue
Diode Bio-Rad Radiance 2001 confocal laser scanning microscope
using a 60U oil immersion objective. For live cell imaging and photo-
bleaching experiments, cells were plated, transfected and observed in
glass bottom culture dishes (MatTek Corporation) on a Bio-Rad Ra-
diance 2001 confocal microscopy system. A de¢ned region of interest
(ROI) of the living cells was photobleached for 5 min at 100% laser
intensity using a 488 nm argon ion laser of 14 mW, measured at laser
output. A single section was imaged before and after the bleaching.
The thickness of the optical sections was 0.51 Wm.
3. Results
We have previously identi¢ed the highly expressed NF1-
vE43 variant which lacks the complete exon 43 [25]. To de-
termine whether deletion of exon 43 in£uences the subcellular
localization of neuro¢bromin, two expression constructs were
created that respectively contained or lacked exon 43. The
plasmids encoded the C-terminal half of neuro¢bromin (en-
compassing exons 28^49) fused to the C-terminus of GFP
(pEGFP-NF1-E[28^49] and pEGFP-NF1-E[28^49]-vE43,
Fig. 1A). These expression constructs were transiently trans-
fected into COS-7 cells. As a control, the GFP expression
vector alone was transfected in parallel. Subcellular localiza-
tion was studied by confocal laser scanning microscopy. In the
control experiment, GFP alone was distributed di¡usely
throughout both the cytoplasm and the nucleus (data not
shown) as GFP is able to di¡use passively through the nuclear
pore because of its relatively small size (27 kDa). The local-
ization of both NF1-GFP fusion proteins di¡ered signi¢-
cantly. Inclusion of exon 43 resulted in a strong nuclear local-
ization (100% of transfected cells) in addition to a moderate
to faint cytoplasmic localization (Fig. 2A). In addition, small
bright dots within the nucleolus were detected in cells with
large and clearly visible nucleoli. Exclusion of exon 43 com-
pletely abolished the nuclear and nucleolar localization and
only a strong homogeneous cytoplasmic staining was ob-
served (Fig. 2B). Identical results were obtained by transfec-
tion of PLC/PRF/5 cells (data not shown). The same con-
structs were used for live cell imaging in COS-7 cells, which
con¢rmed the localization patterns. A representative example
is given for pEGFP-NF1-E[28^49] in Fig. 3, demonstrating a
series of consecutive optical sections through a cell.
To further determine the amino acid residues necessary for
nuclear import, we constructed mutants of pEGFP-NF1-
E[28^49] and examined their subcellular localization. In a ¢rst
mutagenesis experiment, the ¢rst stretch of basic amino acids
of the bipartite NLS was replaced by alanines (K2534A and
R2535A). In a second mutagenesis reaction also the second
stretch of basic amino acids was mutated (K2547A, R2549A
and R2550A) (Fig. 1B). The localization of these mutated
GFP fusion proteins was examined by confocal microscopy
after transfection into COS-7 cells. Mutation of the ¢rst
stretch of basic amino acids resulted in a diminished ability
to enter the nucleus in comparison to the wild-type fusion
protein. The localization pattern was altered from the charac-
teristic bright nuclear and faint cytoplasmic distribution of the
wild-type construct to a faint nuclear and more brightly
stained cytoplasmic pattern (Fig. 2C). The signal intensity of
the nucleolar dots was also decreased. Mutation of the second
stretch of basic amino acids completely abrogated the ability
of the GFP fusion protein to enter the nucleus (Fig. 2D),
resembling the localization pattern of the exon 43-deleted
GFP construct. These results demonstrate that the bipartite
NLS in exon 43 is necessary and su⁄cient to target the NF1-
derivative fusion protein to the nucleus.
To determine whether the C-terminal half of neuro¢bromin
was mobile or participated in long-lived interactions with cer-
tain cellular structures, live cell imaging was performed using
£uorescence loss in photobleaching (FLIP) experiments. In
FLIP, a small region of the cell is continuously bleached by
a high-powered laser pulse, and loss of £uorescence in the
surrounding area is followed over time. pEGFP-NF1-E[28^
49] and pEGFP-NF1-E[28^49]-vE43 expression constructs
Fig. 1. A: Schematic representation of GFP expression constructs
used in this study, indicating the start and the end of the NF1 se-
quence and the position of the spliced exon 43. B: Wild type NLS
(upper sequence), mutation of the ¢rst stretch of amino acids (mid-
dle sequence) and additional mutation of the second stretch of ami-
no acids (lower sequence).
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Fig. 2. Subcellular distribution of GFP-tagged NF1 constructs in transfected COS-7 cells examined by confocal laser scanning microscopy.
Upper panels: DAPI staining of the nuclei; middle panels: images of GFP-tagged NF1 constructs; lower panels: merge of DAPI staining and
GFP expression constructs. A: Subcellular localization of pEGFP-NF1-E[28^49]. Presence of exon 43 results in a strong nuclear localization
and faint cytoplasmic localization. Small dots were detected in the nucleolus. B: Subcellular localization of pEGFP-NF1-E[28^49]-vE43. Ab-
sence of exon 43 completely abolishes the nuclear localization and only a homogeneous cytoplasmic staining is observed. C: Subcellular local-
ization of pEGFP-NF1-E[28^49]-K2534A/K2535A. Mutation of the ¢rst stretch of basic amino acids results in a diminished ability to enter the
nuclear compartment. D: Subcellular localization of pEGFP-NF1-E[28^49]-K2534A/R2535A/K2547A/R2549A/R2550A. Additional mutation of
the second stretch of basic amino acids completely abrogates the ability of the GFP fusion protein to enter the nucleus.
Fig. 3. Live confocal z-series through COS-7 cells transfected with pEGFP-NF1-E[28^49]. Distance between the di¡erent consecutive optical
sections is 0.96 Wm. A bright dot in the nucleolus is indicated by an arrow.
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were transiently transfected into COS-7 cells. When a small
ROI in the cytoplasm (for both constructs) or nucleus (only
for pEGFP-NF1-E[28^49]) was subjected to FLIP, part of the
£uorescence in the bleached compartment (cytoplasm or nu-
cleus) outside the ROI decreased over time. However, a part
of the £uorescence signal was resistant, even after extended
bleaching (Fig. 4). This indicates that part of the fusion pro-
tein moves freely through the cytoplasm or nucleus, while
another part is immobilized. Bleaching a cytoplasmic region
did not trigger loss of £uorescence in the nucleus, even after
an extended period of bleaching, suggesting that it is di⁄cult
for the fusion protein to di¡use out of the nucleus. As a
control FLIP of formaldehyde-¢xed cells that were transfected
with the same constructs resulted in a prominent bleached
area without any bleaching outside the selected region (data
not shown).
4. Discussion
Cells employ a multitude of strategies to ensure that their
proliferation is highly regulated. Therefore tumor suppressor
proteins are regulated at multiple levels including regulated
transcription, post-translational modi¢cations, regulated pro-
tein degradation and regulated nuclear transport. Many tu-
mor suppressors shuttle between the nucleus and the cyto-
plasm. Among them are p53, p73, BRCA1, APC, VHL,
Smad4, Beclin, p130 [26] and NF2 [27]. Small proteins
(6 45 kDa) can di¡use freely into and out the nucleus, where-
as proteins with a larger molecular mass are actively trans-
ported through the nuclear pores by means of their NLS.
Nuclear transport has been proven to be a fundamental and
critical mechanism for regulating protein localization and
function for many tumor suppressor genes. Deregulation of
nuclear transport is implicated in the mislocalization and al-
tered function of a variety of proteins and can have severe
cellular consequences and can potentially lead to the initiation
and progression of cancer [21].
In this study we have identi¢ed a functionally active bipar-
tite NLS in neuro¢bromin which was necessary and su⁄cient
to target a NF1-GFP fusion protein, containing the C-termi-
nal half of NF1, to the nucleus. Mutation of this sequence
results in a total exclusion from the nucleus. In order to pro-
vide insight into the dynamic properties or associations of the
NF1-GFP fusion protein, live cell photobleaching studies
were performed. These FLIP experiments show that part of
the NF1-GFP fusion protein is mobile and moves freely in the
nucleus or cytoplasm, while another part is immobilized. Cy-
toplasmic FLIP did not trigger loss of £uorescence in the
nucleus even after extended cytoplasmic bleaching.
The presence of the NF1 fusion protein in the nucleus is
very intriguing in light of the importance of nucleocytoplas-
mic shuttling for the function and regulation of many tumor
suppressor genes. The possible function of neuro¢bromin
within the nucleus remains unknown. Translocation to the
nuclear compartment could be a mechanism to regulate the
GAP function of neuro¢bromin by sequestration in the nu-
cleus, as Ras is located at the plasma membrane. Sequestra-
tion of NF1 in the nucleus could have important therapeutic
consequences. Exploration of the triggers that initiate nuclear
export could then provide clues for targeted therapeutic inter-
vention. Interestingly, the NF1-vE43 variant, unable to enter
the nucleus, had a very high level of expression in lung, liver,
placenta, fetal liver, kidney and skeletal muscle [25]. These
tissues are not typically associated with NF1 pathology and
it is tempting to hypothesize that a dosage e¡ect due to nu-
clear exclusion exists in these tissues. On the other hand,
neuro¢bromin itself may have a function in the nucleus.
This hypothesis is attractive as the role of the large NF1
protein in cellular proliferation and di¡erentiation has not
yet been fully resolved.
The NF1 fusion protein was concentrated in the nucleoli as
small bright dots. However, excessive amounts of this fusion
protein may compromise a proper subnuclear localization and
a detailed study of NF1 in its natural biological context is
needed in order to interpret these foci.
The existence of a highly expressed splice variant that spe-
ci¢cally lacks the NLS (NF1-vE43) indicates that the local-
ization of neuro¢bromin, and hence its function, can be con-
trolled by alternative splicing in certain tissues. This splicing is
an important regulatory mechanism and may be di¡erentially
regulated at di¡erent developmental stages, in di¡erent phases
of the cell cycle or by speci¢c intra- or extracellular stimuli.
Expression of the NF1-vE43 variant is lower in neural versus
non-neural tissues [20]. This may imply that nuclear localiza-
tion is important in neural tissues. So far, neuro¢bromin has
been mainly considered as a cytoplasmic protein, with only a
few studies reporting some nuclear localization. Nevertheless,
nuclear staining for neuro¢bromin has been reported in devel-
oping neurons [22], in a subset of neurons in adult rat dorsal
root ganglia [12], in a subset of NIH3T3 ¢broblasts [23] and
in di¡erentiating keratinocytes [24].
Regulation of localization can occur at the level of mRNA
processing, by splicing out the NLS-containing exon 43, but
also at the protein level. Several mechanisms can determine
the localization at the protein level. First, a protein domain,
such as a nuclear export signal (NES), can mediate transport
out of the nucleus. Our expression constructs contained the C-
terminal half of neuro¢bromin and a NES situated more N-
terminally might be present in neuro¢bromin. Second, inter-
or intramolecular masking of the transport signal could reg-
ulate localization. BRCA1 has been shown to be retained in
the nucleus through masking of its NES by binding of the
protein BARD1 [28]. Similarly, masking of the NLS in neuro-
¢bromin may prevent its entrance into the nucleus. Third, it
has been shown for some proteins that phosphorylation of
sequences £anking the NLS signal can regulate the NLS-medi-
Fig. 4. FLIP analysis in COS-7 cells transfected with the pEGFP-
NF1-E[28^49] construct. A cytoplasmic and a nuclear de¢ned region
(white zones) were continuously bleached for 5 min and images
were made immediately before (A) and after (B) photobleaching.
After FLIP a decreased £uorescence is seen outside the ROI.
FEBS 28092 17-2-04 Cyaan Magenta Geel Zwart
I. Vandenbroucke et al./FEBS Letters 560 (2004) 98^102 101
ated nuclear import [21]. NF1 contains a casein kinase II and
a tyrosine kinase phosphorylation site very close to the nu-
clear targeting sequence and neuro¢bromin has been reported
to be phosphorylated in vitro [29], although the speci¢c con-
sequences of these phosphorylations, e.g. with respect to local-
ization, have not yet been characterized. Finally, sequestration
in the cytoplasm, by association with binding partners, can
also a¡ect the localization. This form of regulation in£uences
the nucleocytoplasmic shuttling of APC, where the C-termi-
nus exhibits a tight association with cytoskeletal microtubules
[30]. Cytoplasmic anchorage through interaction with speci¢c
binding partners (e.g. microtubules and Ras) could promote
the cytoplasmic retention of neuro¢bromin. Proper control of
nuclear import and export is likely to be an important regu-
lator of neuro¢bromin function. Further examination of the
regulation of localization and analysis of possible associations
within this compartment may yield important clues about
unknown functions of neuro¢bromin.
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